TickerFacts.

Agenus Inc (AGEN): Long-Term Debt

Annual figures by period end, from SEC filings.

$44.66M
As of 2025-12-31
$30.07M
As of 2026-06-30
-9.0%
10-year compound annual growth
$114.47M2014-12-31: $6.03M2015-12-31: $114.47M2024-12-31: $33.17M2025-12-31: $44.66M$44.66M
2014-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$44.66M+34.6%2026-03-16, Balance as of period end
2024-12-31$33.17Mn/a2026-03-16, Balance as of period end
No annual figure between 2015-12-31 and 2024-12-31.
2015-12-31$114.47Mn/m2016-03-15, Balance as of period end
2014-12-31$6.03Mn/a2016-03-15, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Agenus Inc (AGEN)2025-12-31$44.66M+34.6%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a
Fennec Pharmaceuticals Inc. (FENC)2024-12-31$19.34M-37.5%
Editas Medicine, Inc. (EDIT)2024-12-31$57.43Mn/a
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$75.00M0.0%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%
ADMA Biologics, Inc. (ADMA)2025-12-31$72.14M-0.3%
Alector, Inc. (ALEC)2025-12-31$10.00M0.0%
Repligen Corp (RGEN)2025-12-31$542.21M+3.2%

Compare AGEN, ADAPY, FENC, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗